Skip to content
Monday 31 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
0.00%
CAC 40
8,401.18
0.00%
STOXX 50
6,485.67
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Sunday 17 June 2012 10:59 pm

New banking regulation mustn’t be the medicine that killed the patient

By: KCS-content

Add as a preferred source on Google

IN THE four years since the start of the financial crisis, we have walked a tightrope between enough and too much regulation; between the commendable aim of protecting consumers, markets and financial stability on the one hand, and the tendency of politicians, looking to voter concerns and media headlines, to be seen “to do something”.

That is understandable. But the challenge is to do the right thing – drawing a medical analogy, to cure the disease, to inoculate against relapses, but to avoid killing the patient through invasive surgery and overdoses of strong medicine.

The function of banking, but also of insurance, asset management, the derivative markets and other areas of City business, is to allocate and manage capital so it performs an economic function – or more simply, to make the domestic, European and global economy work.

There has been a mismatch between intent and delivery over the past few years, and we are still seeing the consequences. Some of the remedies are policy tools and we can applaud the decisiveness of the chancellor and the governor of the Bank of England – their decision last week to open up the flow of capital, through the banks and out to the wider economy, may have echoes of accident and emergency, but if it supports the patient’s recovery then few will argue.

But it is vital to get the longer term treatment right. The tourniquet has only a limited place in modern medicine. Demanding that banks and, indeed, insurers hold ever-higher capital buffers may reduce systemic risk – but, at a time when capital is scarce anyway, there is a danger of less being available to fund the growth of smaller companies, the development of intellectual property, the expansion of world trade. If the tourniquet of regulation is too tight, the capital won’t flow.

So, as we move to put into place the new regulatory structures under the oversight of the Bank of England, and at a time of great economic and political risk, policymakers need to be acutely conscious of the danger of over-treatment. There are some good signs: the Financial Services Authority has accepted that high quality and independent-minded individuals will be deterred from serving as non-executive directors if the process to clear and authorise them is too rigorous and prescriptive. The proposals to ring-fence retail and commercial banking set out in the government white paper can work given time, pragmatism and the acceptance by government that capital flows should be encouraged, not inhibited. On the fiscal front, the direction of travel on corporation tax is favourable.

Financial services business is not a conspiracy against the common good. Effective supervision and proportionate regulation will reinforce the wider economy, not damage it.

Mark Boleat is policy chairman at Canada Corporation.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Opinion

Categories

  • Opinion

Related Topics

  • NULL

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • City firms mandate phone and face-to-face comms bootcamps for Gen Z lawyers

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Jamie Vardy bags Bundesliga rights as he steps up streaming war with Neville and Lineker

  • Wine to buy this week: The very best Pinot Noir on the shelves

More from Morning Wire

  • Limbic Becomes First AI-Led Mental Healthcare Company Selected for FDA TEMPO

    Business Wire
  • Government pushes Bank of England to innovate on payments and digital currencies

    Regulation
    Bank of England building on Threadneedle Street, London, showcasing its historic architecture and financial significance
  • Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

    Business Wire
  • Why investors shouldn’t rush to buy the next blockbuster IPO

    Opinion
    Excited executives celebrating a SpaceX IPO at Nasdaq with confetti falling and fists raised
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Natwest wins approval to beef up US presence

    Banking
    NatWest bank logo prominently displayed on a modern glass building, reflecting the financial institutions corporate identity.
  • Revolut lands fresh banking licence after wrestling with Europe friction

    Fintech
    Revolut Banque Française ad on a Morris column in Paris, with the July Column and blurred traffic in the background.
  • Zilch, Clearscore among five UK scale-ups to get dedicated FCA support

    Tech
    PhilandSean ZilchCo founders discussing business strategy in an office setting, highlighting innovative leadership and tea...
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook